(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
What to know as New York City nurses strike for a 3rd day - 2Where is Santa right now? NORAD tracks his 2025 Christmas Eve flight.
- 3Banks for High Fixed Store Rates: Amplify Your Reserve funds
- 4Minneapolis ICE shooting live updates: Protests continue over agent's killing of Renee Nicole Good; Walz puts National Guard on standby
- 5Well known Worldwide Caf\u00e9s to Experience
- Flu illness count nears 5 million, with New York City among the hardest hit
- What is colostrum? And should you be taking it?
- Scientists are getting our robotic explorers ready to help send humans to Mars
- Aurora chaser catches a fox basking in the glow of Finland's legendary 'fox fires' (photos)
- Genome study reveals milestone in history of cat domestication
- The Incomparable Advanced cameras: Which One Will Win?
- Getting Your Youngsters' Future: Grasping Legacy Regulations
- Viable Correspondence: Building Solid Connections
- Health insurance premiums rose nearly 3x the rate of worker earnings over the past 25 years
